Navigation
banner

Cancer Therapeutics & Partnering Summit 2017

2017-10-242017-08-282017-07-28
Register 3 for the price of 2 with the coupon code rcdvb!


MENTORS
Alan Epstein

Alan Epstein
Professor, Department of Pathology
Keck School of Medicine of USC
Alan Epstein
Professor, Department of Pathology
Keck School of Medicine of USC
 
About Mentor:

Alan L. Epstein was actively involved in cancer research projects by the age of 16 and participated in the Roswell Park Memorial Institute summer science high school program. He received his BA degree from Wesleyan University, Middletown, CT in 1971 and his MD/PhD degrees from the Medical Scientist Training Program at Stanford University School of Medicine in 1978 under the tutelage of the late Dr. Henry S. Kaplan. Upon graduating Medical School, he won the Hubert H. Humphrey Distinguished Research Fellowship from the Damon Runyon-Walter Winchell Cancer Fund to study in the laboratory of Dr. Theodore Puck at the Eleanor Roosevelt Institute for Cancer Research at the University of Colorado School of Medicine. In 1980, Dr. Epstein joined the medical staff of Northwestern University School of Medicine, Chicago, IL as Assistant Professor in the Division of Medical Oncology where he was awarded the Junior Faculty Research Award from the American Cancer Society and the prestigious Searle Scholar Award. In 1984, he moved to the USC Keck School of Medicine and completed a residency training in Clinical Pathology. He was promoted to full Professor with tenure at USC in 1993. His major research interests include the study of the human malignant lymphomas and leukemias and the use of monoclonal antibodies for the diagnosis and therapy of human solid tumors. He currently is the holder of 30 patents, has published over 160 articles in the field of cancer research, and is the inventor of several monoclonal antibodies which are in clinical trials.

Leslie Khawli

Leslie Khawli
Professor of Clin Pathology, Department of Pathology
Keck School of Medicine of USC
Leslie Khawli
Professor of Clin Pathology, Department of Pathology
Keck School of Medicine of USC
 
About Mentor:

Leslie A. Khawli has over 25 years of academic and industrial experience. He received his Bachelors of Sciences degree in Biology from the American University of Beirut, Lebanon, followed by a Masters of Sciences degree in Chemistry. He then went to receive his Ph.D. in Bioorganic Chemistry from the University of Southern California (USC), Los Angeles, CA in 1986. In the same year he was awarded the National Research Service Award from the NIH, a two-year postdoctoral fellowship in Experimental Nuclear Medicine, which he tenured at Harvard Medical School, Boston, MA. Dr. Khawli then joined the Faculty at the Keck School of Medicine of USC in 1988 as an Assistant Professor of Pathology and rose to the rank of Full Professor in 2001. Over his tenure he had wide range of academic and administrative activities, while maintaining a basic research laboratory, and serving as a leader in a variety of graduate and medical programs aimed to train students and young researchers for careers in academic or biotech. In 2006, he successfully made a switch to the biotechnology industry and joined Genentech/Roche to pursue his interests in cross functional principles of drug development. This transition also allowed him to gain further responsibilities for leading a wide range of scientists to conduct preclinical and translational strategic studies in multiple therapeutic programs. Despite the success of his work at Genentech/Roche, Dr. Khawli returned to USC in 2014 so he could translate his real-industrial experience into an academic role. His research revolves around the interface of chemistry and biology, specifically in the design, characterization and delivery of antibodies as therapeutics and radio-imaging probes. A major focus is on increasing the value of mechanistic ADME studies - from the characterization of physicochemical and functional properties of novel antibodies, ADCs, fusion proteins and biosimilars, to the possible effects on the pharmacokinetics, biodistribution and metabolism, while ensuring safety and efficacy. Dr. Khawli has published over 100 articles and book chapters in the fields of antibody research and development, and he is co-inventor of several patents pertaining to antibody-targeted delivery of drugs and immunomodulatory molecules, and to novel synthetic approaches of radiochemical probes for imaging.

Kamala Maddali

Kamala Maddali
Vice President, Biopharm Collaborations and Companion Diagnostics
Cancer Genetics, Inc.
Kamala Maddali
Vice President, Biopharm Collaborations and Companion Diagnostics
Cancer Genetics, Inc.
 
About Mentor:

Dr. Maddali is currently Vice President, Biopharma Collaborations, Market Development and Companion Diagnostics at Cancer Genetics Inc. In addition, Dr. Maddali is the Vice Chair of the Philadelphia Chapter of Women in Bio. She is also a Scientific Advisory Member for International Cancer Advocacy Network. Her background includes time at Quest Diagnostics, Quintiles and Merck Schering Plough in the arena of biomarkers and companion diagnostics. Dr. Maddali holds a Ph.D. in Pharmacology from University of Missouri-Columbia and a DVM from Acharya N.G. Ranga Agricultural University in India. Dr. Maddali loves to travel with her family which includes her husband, Vamsi and son, Venkat. She enjoys music and watching cartoons at her leisure and engaging in many non-profit activities to create cancer awareness.

Charles Theuer

Charles Theuer
President and CEO
TRACON Pharmaceuticals
Charles Theuer
President and CEO
TRACON Pharmaceuticals
 
About Mentor:

Dr. Theuer joined TRACON as its President and Chief Executive Officer, and a member of its board of directors, in July 2006. Previously, Dr. Theuer was Chief Medical Officer at TargeGen Inc, where he led the development of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Dr. Theuer led the clinical development of Sutent® (sunitinib maleate) in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in January, 2006 for treating advanced kidney cancer. Dr. Theuer also held senior positions at IDEC Pharmaceuticals, where he contributed to the clinical development of Rituxan® and Zevalin®, and the National Cancer Institute. Dr. Theuer holds a B.S. degree from MIT, M.D. degree from UC San Francisco and Ph.D. degree from UC Irvine. He completed a residency in general surgery at Harbor-UCLA Medical Center. Dr. Theuer held academic positions at the National Cancer Institute and at UC Irvine, where he was a member of the Division of Surgical Oncology. He is currently an Associate Clinical Professor in the Division of Epidemiology, Department of Medicine, at UC Irvine. His previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients as well as cancer epidemiology.